Cue Biopharma Registers Resale of 4.1M Shares from Deeply Discounted Private Placement
Summary
Cue Biopharma filed an S-3 to register the resale of 4.1 million shares of common stock, including shares underlying pre-funded warrants and warrants, issued in a private placement that closed on May 4, 2026. This registration enables investors to sell shares from a highly dilutive transaction that provided $28 million in net proceeds to the company.
Key Events
-
Resale Registration Filed
Cue Biopharma filed an S-3 registration statement for the resale of up to 4,090,908 shares of common stock by selling stockholders. These shares were issued in a private placement that closed on May 4, 2026.
-
Significant Potential Dilution
The 4,090,908 shares registered for resale represent approximately 97.4% of the 4,200,343 shares outstanding as of June 1, 2026, creating a substantial overhang on the stock.
-
Private Placement Details
The underlying private placement, which closed on May 4, 2026, involved the sale of pre-funded warrants and warrants at a price of $11.00 per unit, generating approximately $28.0 million in net proceeds for the company.
-
No Direct Proceeds from Resale
The company will not receive any proceeds from the sale of shares by the selling stockholders, except for the $11.00 exercise price per share if the warrants are exercised for cash.
Analysis
This S-3 filing formalizes the ability of investors from a recent private placement to sell a substantial number of shares. While the $28.0 million capital raise from the private placement was critical for the company, which had previously disclosed "going concern" doubts, the terms were highly dilutive. The 4.1 million shares registered for resale represent nearly 100% of the currently outstanding shares, creating a significant potential overhang on the stock. The private placement was priced at $11.00 per unit, a deep discount compared to the current stock price of $26.91, indicating the company's urgent need for capital.
At the time of this filing, CUE was trading at $26.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.9M. The 52-week trading range was $4.97 to $41.42. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.